Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. AXP
10. TMUS

Go back to Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy

Cabaletta Bio Announces 2026 Strategic Priorities

January 12, 2026 8:00 AM EST

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission including an outpatient dosing option using a single weight-based dose 

IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics

New durability data without preconditioning and higher dose initial clinical data from RESET-PV expected in 1H26; dose-ranging data from RESET-SLE without preconditioning anticipated in 2026

Complete Phase 1/2 data anticipated in... More